Patents Examined by Donna L. Barnd
  • Patent number: 5252717
    Abstract: DNA encoding glycoproteins gD, gI and part of gE from Marek's disease herpesvirus is described. The DNA is useful for probes to detect the DNA in the herpesvirus, for expression to produce the glycoproteins can be used for producing the antibodies which specifically recognize the three glycoprotein antigens, and in the case of the latter two genes, for potential insertion sites for foreign genes. Novel glycoproteins and regulatory sequences are also disclosed.
    Type: Grant
    Filed: March 9, 1992
    Date of Patent: October 12, 1993
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Leland F. Velicer, Peter Brunovskis, Paul M. Coussens
  • Patent number: 5252716
    Abstract: DNA encoding glycoproteins gD, gI and part of gE from Marek's disease herpesvirus is described. The DNA is useful for probes to detect the DNA in the herpesvirus, for expression to produce the glycoproteins can be used for producing the antibodies which specifically recognize the three glycoprotein antigens, and in the case of the latter two genes, for potential insertion sites for foreign genes. Novel glycoproteins and regulatory sequences are also disclosed.
    Type: Grant
    Filed: March 4, 1992
    Date of Patent: October 12, 1993
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Leland F. Velicer, Peter Brunovskis, Paul M. Coussens
  • Patent number: 5241052
    Abstract: Disclosed is carcinoma orosomucoid-related antigen (CORA), a glycoprotein which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and is characterized by having a molecular weight of about 46,000-50,000 daltons on SDS-polyacrylamide gels, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, an amino acid sequence defined in the Sequence Listing by SEQ ID NO:1, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed is a method for detecting and monitoring carcinoma.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: August 31, 1993
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Carol A. Toth, Peter Thomas